home / stock / agle / agle quote
$0.4874 Last:
16.05% Change Percent:
$0.5 Open:
$0.42 Previous Close:
$0.516 High:
$0.4831 Low:
317,085 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Stock Date | Open Price | Close Price | High | Low | Volume |
---|---|---|---|---|---|
2022-08-15 | 0.5 | 0.42 | 0.516 | 0.4831 | 317,085 |
2022-08-12 | 0.4849 | 0.42 | 0.52 | 0.4624 | 445,518 |
2022-08-11 | 0.47 | 0.42 | 0.518 | 0.45 | 952,955 |
2022-08-10 | 0.42 | 0.42 | 0.4699 | 0.41 | 3,197,462 |
2022-08-09 | 0.42 | 0.42 | 0.45 | 0.401 | 287,192 |
2022-08-08 | 0.441 | 0.42 | 0.451 | 0.42 | 205,766 |
2022-08-05 | 0.43 | 0.42 | 0.43 | 0.4157 | 282,285 |
2022-08-04 | 0.41 | 0.42 | 0.42 | 0.395 | 276,951 |
2022-08-03 | 0.4029 | 0.42 | 0.4257 | 0.389 | 422,150 |
2022-08-02 | 0.395 | 0.42 | 0.3957 | 0.372 | 161,238 |
2022-08-01 | 0.41 | 0.42 | 0.41 | 0.39 | 200,924 |
2022-07-29 | 0.4158 | 0.42 | 0.4295 | 0.4 | 171,235 |
2022-07-28 | 0.42 | 0.42 | 0.43 | 0.4056 | 231,326 |
2022-07-26 | 0.4386 | 0.4386 | 0.4401 | 0.4 | 115,819 |
2022-07-25 | 0.4366 | 0.4094 | 0.4389 | 0.4094 | 99,656 |
2022-07-19 | 0.4647 | 0.4763 | 0.4864 | 0.4644 | 164,395 |
2022-07-18 | 0.4693 | 0.461 | 0.4799 | 0.4564 | 85,000 |
2022-07-15 | 0.47 | 0.4689 | 0.4822 | 0.46 | 249,754 |
2022-07-14 | 0.48 | 0.47 | 0.5022 | 0.4526 | 252,530 |
2022-07-13 | 0.483 | 0.4821 | 0.5076 | 0.48 | 533,386 |
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates PR Newswire Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forwar...
Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnol...
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market PR Newswire AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company ...